We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection.
- Authors
Lange, Anna; Thunberg, Ulrica; Söderquist, Bo
- Abstract
Background: Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment. The extended half-life, good penetration into bone and synovial fluid, and bactericidal activity against gram-positive bacteria, including those in biofilm, make dalbavancin an appealing choice for treatment of bone and joint infections in outpatient settings. However, we present a rare case of ototoxicity associated with off-label extended dalbavancin treatment of a prosthetic joint infection. Case presentation: A 55-year-old man with a prosthetic joint infection of the shoulder underwent off-label extended dalbavancin treatment, receiving a cumulative dose of 2500 mg. The patient experienced a gradual onset of hearing loss following the first dose, leading to a diagnosis of bilateral sensorineural hearing loss that persisted 1 year after dalbavancin was discontinued. Conclusions: This case report highlights the importance of exercising caution when administering dalbavancin beyond approved dosing guidelines, and emphasizes the need for vigilance regarding the potential for ototoxicity.
- Subjects
ARTIFICIAL joints; JOINT infections; SHOULDER joint; SOFT tissue infections; OTOTOXICITY; SENSORINEURAL hearing loss
- Publication
BMC Infectious Diseases, 2023, Vol 23, Issue 1, p1
- ISSN
1471-2334
- Publication type
Article
- DOI
10.1186/s12879-023-08709-8